Key result
Sugammadex effectively reversed rocuronium-induced neuromuscular blockade in ESRD patients, though recovery to a TOF ratio ≥0.9 was prolonged compared to normal renal function.
Why the study?
Most drugs display altered pharmacokinetics and reduced clearance in compromised kidney function, prompting an evaluation of the efficacy, pharmacokinetics, and safety of sugammadex in patients with ESRD undergoing general anesthesia.
Does sugammadex effectively and safely reverse rocuronium-induced neuromuscular blockade in patients with end-stage renal disease compared to patients with normal renal function?
Meta-Analysis (n=655)
Does sugammadex effectively and safely reverse rocuronium-induced neuromuscular blockade in patients with end-stage renal disease compared to patients with normal renal function?
Sugammadex effectively and safely reverses rocuronium-induced neuromuscular blockade in ESRD patients, though recovery time to a TOF ratio of 0.9 is slightly prolonged by about 1.14 minutes compared to patients with normal renal function.
Answers are grounded in this paper and cite their sources.
May support sugammadex consideration in ESRD with TOF monitoring; leaves open confirmation in randomized trials.
Background and Objectives: Sugammadex is widely used in anesthesia to reverse rocuronium-induced neuromuscular blockade (NMB). In patients with compromised kidney function, most drugs show alteration of their pharmacokinetic profile with reduced clearance. The purpose of this article is to examine the efficacy, pharmacokinetics, and safety of sugammadex in end-stage renal disease (ESRD) patients receiving general anesthesia, using a systematic review. Materials and Methods: The databases of PubMed, EMBASE, the Cochrane Library, Web of Science, Scopus, KoreaMed, and ClinicalTrials.gov were searched for studies comparing the efficacy or safety outcomes of sugammadex administration for the reversal of rocuronium-induced NMB, in ESRD patients (group R) or in those with normal renal function (group N) undergoing surgery under general anesthesia. Results: We identified nine studies with 655 patients—six prospective, case-control studies with 179 patients (89 and 90 in groups R and N) and three retrospective observational studies with 476 ESRD patients. In the six prospective studies, the times taken to reach a train-of-four ratio ≥0.9, 0.8, and 0.7 were significantly longer in group R than in group N (weighted mean difference [95% confidence interval] [min]: 1.14 [0.29 to 2.00], 0.9 [0.24 to 1.57], 0.89 [0.20 to 1.57], respectively). The total plasma clearance of sugammadex was significantly lower in group R than in group N. There was no significant difference in the incidence of NMB recurrence and prolonged time to recovery between the groups. In the three retrospective studies, the possibility of sugammadex-related adverse events appears to be insignificant. Conclusions: Sugammadex may effectively and safely reverse rocuronium-induced NMB in patients with ESRD, although the recovery to a TOF ratio of 0.9 may be prolonged compared to patients with normal renal function. Further studies are needed, considering the small number of studies included and the high heterogeneity of some of the results.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) conducted a meta-analysis in End-stage renal disease requiring general anesthesia (n=655). Sugammadex vs. Patients with normal renal function was evaluated on Time taken to reach a train-of-four ratio ≥0.9 (WMD 1.14 min, 95% CI 0.29 to 2.00). Sugammadex effectively reversed rocuronium-induced neuromuscular blockade in ESRD patients, though recovery to a TOF ratio ≥0.9 was prolonged compared to normal renal function.
Synapse has enriched 10 related papers. Consider them for comparative context: